Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Biol Ther
Glavni autori: Wen, Feng, Yang, Yu, Zhang, Pengfei, Zhang, Jian, Zhou, Jing, Tang, Ruilei, Chen, Hongdou, Zheng, Hanrui, Fu, Ping, Li, Qiu
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2015
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846122/
https://ncbi.nlm.nih.gov/pubmed/26418570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095398
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items